<DOC>
	<DOCNO>NCT00457678</DOCNO>
	<brief_summary>The purpose study demonstrate Visudyne-Lucentis-dexamethasone ( V-L-D ) triple therapy give similar efficacy safety result Lucentis monotherapy .</brief_summary>
	<brief_title>Second Line Therapy Treat Age-related Macular Degeneration ( AMD ) Patients Not Responding Well Lucentis Therapy Itself</brief_title>
	<detailed_description>Study Design : Patients receive 2-6 previous treatment Lucentis monotherapy exudative activity associate choroidal neovascularization ( CNV ) lesion , confirm fluorescein angiography ( FA ) optical coherence tomography ( OCT ) , eligible . Patients randomly assign 4-8 week previous Lucentis treatment either 1. continuation Lucentis monotherapy 2. triple therapy half fluence Visudyne ( 300 mW/cm2 83 second ) follow within 2 hour intravitreal Lucentis 0.5 mg ( first injection ) dexamethasone 0.5 mg ( second injection ) ( V-L-D ) . Both group receive treatment baseline need ( PRN ) , accord retreatment criterion , monthly assessment thereafter 12 month . In triple therapy group , patient may retreat V-L-D combination interval less 3 month ; retreatment need 1 2 month previous V-L-D treatment , patient receive Lucentis injection visit ; however , retreatment need previous V-L-D treatment least 3 month prior , V-L-D treatment mandatory . OCT , visual acuity ( VA ) testing , possibly FA conduct assessment visit define need retreatment .</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Verteporfin</mesh_term>
	<criteria>Main Patients subfoveal CNV due AMD , 26 previous treatment Lucentis monotherapy , continue exudative activity associate CNV lesion 48 week last treatment . Exudative activity define one : CNV leakage confirm FA New hemorrhage associate CNV lesion Subretinal fluid cystoid macular edema OCT show retinal thickness ≥ 230 μm All lesion composition type lesion great linear dimension ( GLD ) ≤ 5400 micron ( approximately ≤ 9 disc area [ DA ] ) Best correct ETDRS VA score 2573 letter ( approximate Snellen equivalent 20/4020/320 ) Main Subfoveal geographic atrophy subfoveal fibrosis study eye Intraocular surgery within 3 month enrollment Inability attend protocolrequired visit Known allergy hypersensitivity study treatment</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Vision loss</keyword>
	<keyword>Retina</keyword>
	<keyword>VEG-F</keyword>
	<keyword>Fovea</keyword>
	<keyword>AMD</keyword>
</DOC>